CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 59 enrolled
Drug / intervention
Erlotinibdrug
Likely dose
Erlotinib 150 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00410059
NCT00410059Phase 2Completed
CompareCT.gov

A Phase II, Open Label Study of Erlotinib (Tarceva) in Previously Treated Subjects With Advanced Non-Small Cell Lung Cancer

M.D. Anderson Cancer Center·interventional·Posted Dec 12, 2006·Updated Aug 2, 2017

In Brief

A Phase 2 clinical trial evaluating Erlotinib for Lung Cancer. Completed, enrolled 59 participants across 1 site.

Detailed Summary

The goal of this clinical research study is to learn if erlotinib hydrochloride (OSI-774, Tarceva®) can help to control NSCLC. The safety of this drug will also be studied, as well as the drug's effect on different cells in the body and the participants' overall response.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer
CountriesUnited States
CollaboratorsUnited States Department of Defense

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 12, 2006
Enrollment StartNov 1, 2006
Primary CompletionJul 1, 2016
TodayJul 2, 2026
Enrollment to primary: 9.7 yearsPosted 19.6 years ago

Interventions

Erlotinibdrug

150 mg by mouth daily x 28 days